Clinical trial

Bacterial Decolonization to Prevent Radiation Dermatitis: A Randomized Controlled Trial and Quality of Life Assessment

Name
2018-9722
Description
The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
Trial arms
Trial start
2019-06-03
Estimated PCD
2021-12-02
Trial end
2021-12-02
Status
Completed
Phase
Early phase I
Treatment
Chlorhexidine gluconate solution
Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Arms:
Treatment Arm
Mupirocin Ointment
Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Arms:
Treatment Arm
Size
80
Primary endpoint
Number of Participants With Incidence of High Grade Radiation Dermatitis
Last treatment session (study week depends on patient's length of treatment), approximately 5 to 8 weeks
Median Change in Quality of Life Scoring Rated by the Skindex-16 Dermatological Survey
From the first week (week 1) to the last week of treatment (study week depends on patient's length of treatment), approximately 5 to 8 weeks
Eligibility criteria
Inclusion Criteria: * Age ≥ 18 * Diagnosis of a solid tumor of the breast or head and neck with plans for fractionated radiation therapy (≥ 15 fractions) with curative intent Exclusion Criteria: * Prior RT to the region of interest * Existing dermatologic condition affecting the treatment area (eg: atopic dermatitis, psoriasis, and non-healing wounds) * Known allergy to chlorhexidine or mupirocin
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 80, 'type': 'ACTUAL'}}
Updated at
2023-11-13

1 organization

2 products

1 indication

Product
Mupirocin